Entropy Neurodynamics Ltd Granted Australian Psilocin Crystalline Forms Patent
Australian patent granted for Entropy’s proprietary psilocin crystalline forms
The Australian Patent Office has granted Entropy Neurodynamics (ASX: ENP) Australian Standard Patent No. 2023343417, titled “Psilocin Crystalline Forms”. Entropy Neurodynamics is a clinical-stage biotechnology company developing proprietary psilocin formulations for conditions with unmet medical needs.
The patent provides composition-of-matter protection over multiple novel psilocin salt and cocrystal forms. It carries a 20-year term from 12 September 2023 and, subject to payment of applicable renewal fees, is expected to remain in force until September 2043.
For a clinical-stage biotechnology developer, this psilocin patent underpins long-term commercialisation value by protecting the underlying molecular forms at the core of its platform.
When big ASX news breaks, our subscribers know first
What the patent protects
The grant covers several distinct claim categories, extending protection across the molecule, its manufacture and its therapeutic use.
-
Composition-of-matter protection over multiple proprietary crystalline forms of psilocin, including novel salt and cocrystal forms designed to improve stability, solubility and pharmaceutical properties.
-
Claims covering methods of manufacture.
-
Claims covering pharmaceutical formulations.
-
Therapeutic use across a broad range of 5-HT2A receptor-mediated disorders.
According to the company, the grant further strengthens its intellectual property portfolio supporting the development of next-generation psilocin-based therapeutics, including intravenous, oral and other precision-controlled delivery approaches.
CEO Commentary
“Protecting our proprietary intellectual property is a core component of Entropy’s long-term strategy and key to advancing as our precisioncontrolled platform. This patent strengthens our composition-of-matter protection around novel psilocin crystalline forms that have the potential to deliver important pharmaceutical advantages, including enhanced stability and solubility, key components to ongoing drug development and commercialisation. Combined with our broader international patent strategy, this grant further reinforces the value of our platform and supports future commercialisation opportunities across multiple therapeutic indications.” said Jason Carroll, Chief Executive Officer.
Why psilocin IP matters to investors
Psilocin is the active metabolite of psilocybin, the compound found in certain psychedelic mushrooms. Entropy is developing it for a range of neuropsychiatric conditions in combination with psychotherapy.
Why do crystalline forms matter? Different crystalline arrangements of the same molecule can offer improved stability and solubility, two properties that directly affect how a drug can be manufactured, stored and delivered to patients.
This grant strengthens an existing portfolio rather than establishing one from scratch.
How this fits Entropy’s global IP and clinical strategy
The Australian grant complements Entropy’s broader international intellectual property strategy. The underlying invention is also protected through the company’s international Patent Cooperation Treaty (PCT) application, supporting future patent prosecution across key global markets.
The intellectual property sits behind Entropy’s lead program, TRP-8803, a proprietary formulation of IV-infused psilocin. The candidate is designed to reduce the time to onset of the psychedelic state, control the depth and duration of the experience, and shorten the overall intervention to a commercially feasible timeframe.
The IV psilocin platform at the core of TRP-8803 delivers onset within 15 minutes and limits total treatment sessions to 1-2 hours, compared to the 8-10 hour commitment required by oral psilocybin, a difference with direct implications for clinic throughput and commercial scalability.
Development of TRP-8803 follows a number of Phase 2a clinical trials using oral psilocybin across Binge Eating Disorder, Irritable Bowel Syndrome and Fibromyalgia. The company states results from those trials demonstrated the clinical benefits of psychedelic therapy and are being used to inform the development of TRP-8803.
| Feature | Detail |
|---|---|
| Patent number | Australian Standard Patent No. 2023343417 |
| Title | “Psilocin Crystalline Forms” |
| Protection type | Composition-of-matter |
| Term start | 12 September 2023 |
| Expiry | September 2043 (subject to renewal fees) |
The next major ASX story will hit our subscribers first
What comes next
According to management, the grant reinforces the value of Entropy’s platform and supports future commercialisation opportunities across multiple therapeutic indications.
The company continues to advance its precision-controlled psilocin platform and lead candidate TRP-8803, drawing on data from its earlier oral psilocybin trials.
DSMB safety clearance for Cohort 2 progression was granted with no protocol modifications after all six Cohort 1 participants completed both dosing sessions with zero serious adverse events, an outcome that validates the tolerability profile of the IV delivery approach the patented crystalline forms are designed to enable.
With composition-of-matter protection now secured in Australia and complementary international coverage in progress, the grant adds a further layer of intellectual property protection around the molecular forms that sit at the heart of Entropy’s long-term platform value.
Ready to Learn More About Entropy Neurodynamics’ Psilocin Platform?
Entropy Neurodynamics has secured a 20-year composition-of-matter patent over novel psilocin crystalline forms, underpinning the long-term commercialisation potential of its lead candidate TRP-8803 and broader precision-controlled delivery platform. With international PCT coverage progressing and clinical momentum building, the intellectual property foundation supporting this neuropsychiatric pipeline continues to strengthen.
Investors seeking a deeper understanding of Entropy’s pipeline, IP strategy and upcoming milestones can explore the full platform at the Entropy Neurodynamics investor centre to assess the opportunity in full.